Abstract
Background & aims
Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19.
Methods
We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as “Remdesivir” or ‘GS-5734″ AND “COVID-19” or “SARS-CoV-2” and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19.
Results
Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality.
Conclusions
Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.
【저자키워드】 COVID-19, Mortality, Remdesivir, Clinical outcome, SARS-Co-V-2, 【초록키워드】 Treatment, Trial, severe COVID-19, SARS-COV-2 infection, randomized trial, in vitro, database, Clinical effect, Wuhan, Time to recovery, in vivo, trials, placebo-controlled, anti-viral drug, compassionate use, double-blind, English language, Side effect, control arm, medRxiv, while, randomized controlled study, effective, benefit, Result, shown, reported, conducted, searched, absence, faster, inhibit SARS-CoV-2, patients with COVID-19, retrieved, 【제목키워드】 Critical, clinical study,